VICTORY: Rosiglitazone and Atherosclerosis The drug showed a trend toward a slowing of the progression of atherosclerosis and an overall positive effect on metabolic factors in the VICTORY study in ...

September 21, 2007 (Amsterdam, the Netherlands) - Pioglitazone (Actos) manufacturer Takeda is trumpeting the results of two in-house studies presented here at the European Association for the Study of ...

A new study published online today by JAMA shows that among patients age 65 years and older, rosiglitazone (a medication for treating Type 2 diabetes) is associated with an increased risk of stroke, ...

Amsterdam, The Netherlands, Sept. 19, 2007 -- New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further ...

Direct and indirect costs for diabetes mellitus place a large economic burden on the US healthcare system. Diabetes and cardiovascular disease (CVD) are closely interrelated, and it is estimated that ...

Manufacturers of certain drugs approved to treat type 2 diabetes have agreed to add an upgraded “boxed” warning emphasizing that the drugs may cause or worsen heart failure in certain patients. FDA’s ...

The pioglitazone safety warning issued in South Korea, which recommended prescribing with careful attention among those with high risk of bladder cancer, led to a moderate decrease in pioglitazone ...

In Sept. 23, 2010, the Food and Drug Administration (FDA) announced that rosiglitazone (Avandia), a diabetes drug manufactured by GlaxoSmithKline (GSK), would be the subject of a stringent Risk ...